Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2011 2
2012 2
2014 2
2015 1
2017 1
2018 2
2019 5
2020 2
2021 2
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Poh ME, Chai CS, Liam CK, Ho GF, Pang YK, Hasbullah HH, Tho LM, Muhamad Nor I, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Soon SY, Tan SN, How SH. Poh ME, et al. Among authors: how sh. Transl Lung Cancer Res. 2024 Feb 29;13(2):307-320. doi: 10.21037/tlcr-23-691. Epub 2024 Feb 28. Transl Lung Cancer Res. 2024. PMID: 38496703 Free PMC article.
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
Reungwetwattana T, Cho BC, Lee KH, Pang YK, Fong CH, Kang JH, Lee YG, Lim CS, Danchaivijitr P, Lim YN, Lee Y, How SH, Geater S, Lee SS, Min YJ, Kim JH, Lee JS, Lee GW, Soo RA, Lee SY, Choi S, Ahn MJ. Reungwetwattana T, et al. Among authors: how sh. J Thorac Oncol. 2023 Oct;18(10):1351-1361. doi: 10.1016/j.jtho.2023.06.016. Epub 2023 Sep 11. J Thorac Oncol. 2023. PMID: 37702629 Free article. Clinical Trial.
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Cho BC, et al. Among authors: how sh. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28. J Clin Oncol. 2023. PMID: 37379502 Clinical Trial.
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.
Poh ME, How SH, Ho GF, Pang YK, Hasbullah HH, Tho LM, Muhamad Nor I, Lim BC, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Soon SY, Tan JYK, Zainal Abidin MA. Poh ME, et al. Among authors: how sh. Cancer Manag Res. 2023 Jan 13;15:31-41. doi: 10.2147/CMAR.S393729. eCollection 2023. Cancer Manag Res. 2023. PMID: 36660237 Free PMC article.
Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country.
How SH, Tho LM, Liam CK, Hasbullah HH, Ho GF, Muhammad Nor I, Poh ME, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Pang YK, Soon SY. How SH, et al. Thorac Cancer. 2022 Jun;13(11):1676-1683. doi: 10.1111/1759-7714.14442. Epub 2022 May 3. Thorac Cancer. 2022. PMID: 35502623 Free PMC article.
Lung Cancer in Malaysia.
Rajadurai P, How SH, Liam CK, Sachithanandan A, Soon SY, Tho LM. Rajadurai P, et al. Among authors: how sh. J Thorac Oncol. 2020 Mar;15(3):317-323. doi: 10.1016/j.jtho.2019.10.021. J Thorac Oncol. 2020. PMID: 32093853 Free article. No abstract available.
25 results